JP2017526619A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017526619A5 JP2017526619A5 JP2016572424A JP2016572424A JP2017526619A5 JP 2017526619 A5 JP2017526619 A5 JP 2017526619A5 JP 2016572424 A JP2016572424 A JP 2016572424A JP 2016572424 A JP2016572424 A JP 2016572424A JP 2017526619 A5 JP2017526619 A5 JP 2017526619A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- cells
- stem cells
- use according
- inflammatory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 16
- 210000000130 stem cell Anatomy 0.000 claims 15
- 210000004027 cell Anatomy 0.000 claims 8
- 210000002540 macrophage Anatomy 0.000 claims 8
- 238000004519 manufacturing process Methods 0.000 claims 6
- 208000024891 symptom Diseases 0.000 claims 6
- 102100034594 Angiopoietin-1 Human genes 0.000 claims 5
- 101000924552 Homo sapiens Angiopoietin-1 Proteins 0.000 claims 5
- 108090001005 Interleukin-6 Proteins 0.000 claims 5
- 230000003110 anti-inflammatory effect Effects 0.000 claims 5
- 206010012601 diabetes mellitus Diseases 0.000 claims 5
- 208000027866 inflammatory disease Diseases 0.000 claims 5
- 210000005087 mononuclear cell Anatomy 0.000 claims 4
- 230000000770 proinflammatory effect Effects 0.000 claims 4
- 108060006698 EGF receptor Proteins 0.000 claims 3
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 2
- 108010048154 Angiopoietin-1 Proteins 0.000 claims 2
- 102000009088 Angiopoietin-1 Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 2
- 210000000068 Th17 cell Anatomy 0.000 claims 2
- 210000004241 Th2 cell Anatomy 0.000 claims 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 2
- 208000033679 diabetic kidney disease Diseases 0.000 claims 2
- 210000002443 helper t lymphocyte Anatomy 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 claims 1
- 102000011690 Adiponectin Human genes 0.000 claims 1
- 108010076365 Adiponectin Proteins 0.000 claims 1
- 201000004569 Blindness Diseases 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 102000001554 Hemoglobins Human genes 0.000 claims 1
- 108010054147 Hemoglobins Proteins 0.000 claims 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims 1
- 210000004322 M2 macrophage Anatomy 0.000 claims 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims 1
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 238000002266 amputation Methods 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 239000008121 dextrose Substances 0.000 claims 1
- 230000004069 differentiation Effects 0.000 claims 1
- 230000009266 disease activity Effects 0.000 claims 1
- 201000001881 impotence Diseases 0.000 claims 1
- 210000004969 inflammatory cell Anatomy 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims 1
- 229960003105 metformin Drugs 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 230000010287 polarization Effects 0.000 claims 1
- 210000003289 regulatory T cell Anatomy 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUAU2014902194 | 2014-06-10 | ||
| AU2014902194A AU2014902194A0 (en) | 2014-06-10 | Treatment of immune disorders | |
| AUAU2014902257 | 2014-06-13 | ||
| AU2014902257A AU2014902257A0 (en) | 2014-06-13 | Treatment of immune disorders 2 | |
| PCT/EP2015/062138 WO2015189063A1 (en) | 2014-06-10 | 2015-06-01 | Treatment of immune disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020195123A Division JP7009594B2 (ja) | 2014-06-10 | 2020-11-25 | 免疫疾患の治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017526619A JP2017526619A (ja) | 2017-09-14 |
| JP2017526619A5 true JP2017526619A5 (cg-RX-API-DMAC7.html) | 2018-07-12 |
| JP6800757B2 JP6800757B2 (ja) | 2020-12-16 |
Family
ID=53385603
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016572424A Active JP6800757B2 (ja) | 2014-06-10 | 2015-06-01 | 免疫疾患の治療 |
| JP2020195123A Active JP7009594B2 (ja) | 2014-06-10 | 2020-11-25 | 免疫疾患の治療 |
| JP2022003013A Active JP7279212B2 (ja) | 2014-06-10 | 2022-01-12 | 免疫疾患の治療 |
| JP2023077363A Active JP7680493B2 (ja) | 2014-06-10 | 2023-05-09 | 免疫疾患の治療 |
| JP2025078086A Pending JP2025109787A (ja) | 2014-06-10 | 2025-05-08 | 免疫疾患の治療 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020195123A Active JP7009594B2 (ja) | 2014-06-10 | 2020-11-25 | 免疫疾患の治療 |
| JP2022003013A Active JP7279212B2 (ja) | 2014-06-10 | 2022-01-12 | 免疫疾患の治療 |
| JP2023077363A Active JP7680493B2 (ja) | 2014-06-10 | 2023-05-09 | 免疫疾患の治療 |
| JP2025078086A Pending JP2025109787A (ja) | 2014-06-10 | 2025-05-08 | 免疫疾患の治療 |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US10624930B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3154565B1 (cg-RX-API-DMAC7.html) |
| JP (5) | JP6800757B2 (cg-RX-API-DMAC7.html) |
| KR (4) | KR20170007854A (cg-RX-API-DMAC7.html) |
| CN (2) | CN114129598A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2015273799B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2950804C (cg-RX-API-DMAC7.html) |
| SG (1) | SG11201609993YA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015189063A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120087933A1 (en) | 2010-10-08 | 2012-04-12 | Samson Tom | Enhanced msc preparations |
| CA2837895C (en) * | 2011-06-03 | 2021-07-27 | Mesoblast, Inc. | Methods of treating or preventing neurological diseases |
| US8961956B2 (en) | 2011-11-30 | 2015-02-24 | Ocata Therapeutics, Inc. | Mesenchymal stromal cells and uses related thereto |
| CN104136034B (zh) | 2011-11-30 | 2018-04-24 | 安斯泰来再生医药协会 | 间充质基质细胞及其相关用途 |
| CN104471059B (zh) | 2012-07-12 | 2018-04-17 | 珠海横琴爱姆斯坦生物科技有限公司 | 人胚胎干细胞衍生的间充质样干细胞、方法及其应用 |
| SG11201609993YA (en) * | 2014-06-10 | 2016-12-29 | Mesoblast Internat Sàrl | Treatment of immune disorders |
| JP7249951B2 (ja) * | 2017-03-31 | 2023-03-31 | ウィスコンシン アラムニ リサーチ ファンデーション | 標的臓器の細胞外構成成分を使用する治療用細胞の作製 |
| CN106929474B (zh) * | 2017-03-31 | 2021-09-14 | 北京恒峰铭成生物科技有限公司 | 一种m2巨噬细胞诱导剂 |
| WO2019108756A1 (en) | 2017-11-29 | 2019-06-06 | Figene, Llc | Interaction of fibroblasts and immune cells for activation and uses thereof |
| CN112007165B (zh) * | 2020-08-27 | 2021-10-08 | 北京大学人民医院 | 巨噬细胞极化调节剂及其在促进血小板生成中的应用 |
| JP2025540288A (ja) * | 2022-12-09 | 2025-12-11 | メゾブラスト・インターナショナル・エスアーエールエル | 細胞組成物を用いた炎症治療方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5486359A (en) | 1990-11-16 | 1996-01-23 | Osiris Therapeutics, Inc. | Human mesenchymal stem cells |
| AU2003901668A0 (en) | 2003-03-28 | 2003-05-01 | Medvet Science Pty. Ltd. | Non-haemopoietic precursor cells |
| US20050239897A1 (en) * | 2004-03-22 | 2005-10-27 | Pittenger Mark F | Mesenchymal stem cells and uses therefor |
| AU2005287855B2 (en) * | 2004-09-24 | 2011-06-16 | Mesoblast, Inc. | Method of enhancing proliferation and/or survival of mesenchymal precursor cells (MPC) |
| WO2006108229A1 (en) | 2005-04-12 | 2006-10-19 | Angioblast Systems, Inc. | Isolation of adult multipotential cells by tissue non-specific alkaline phosphatase |
| CN102076844B (zh) * | 2008-06-30 | 2013-08-07 | 成血管细胞系统公司 | 采用组合疗法的眼病和过度血管新生的治疗 |
| NZ592726A (en) * | 2008-11-19 | 2012-12-21 | Anthrogenesis Corp | Amnion derived adherent cells |
| JP5678360B2 (ja) * | 2009-09-28 | 2015-03-04 | 株式会社ジーシー | 間葉系幹細胞の培養方法 |
| US20140017787A1 (en) * | 2010-10-11 | 2014-01-16 | Aline M. Betancourt | Mesenchymal stem cells and related therapies |
| CN104136034B (zh) * | 2011-11-30 | 2018-04-24 | 安斯泰来再生医药协会 | 间充质基质细胞及其相关用途 |
| CN102899293A (zh) | 2012-11-01 | 2013-01-30 | 上海市肺科医院 | 促血管生成素1基因修饰的间充质干细胞、及其构建方法与应用 |
| AU2015243575B2 (en) * | 2014-04-07 | 2017-11-02 | Mesoblast International Sarl | Improved stem cell composition |
| SG11201609993YA (en) | 2014-06-10 | 2016-12-29 | Mesoblast Internat Sàrl | Treatment of immune disorders |
-
2015
- 2015-06-01 SG SG11201609993YA patent/SG11201609993YA/en unknown
- 2015-06-01 KR KR1020177000032A patent/KR20170007854A/ko not_active Ceased
- 2015-06-01 EP EP15728457.1A patent/EP3154565B1/en active Active
- 2015-06-01 KR KR1020237007387A patent/KR102704978B1/ko active Active
- 2015-06-01 KR KR1020257031878A patent/KR20250143870A/ko active Pending
- 2015-06-01 KR KR1020247029823A patent/KR102865313B1/ko active Active
- 2015-06-01 AU AU2015273799A patent/AU2015273799B2/en active Active
- 2015-06-01 US US15/317,673 patent/US10624930B2/en active Active
- 2015-06-01 CN CN202111351585.8A patent/CN114129598A/zh active Pending
- 2015-06-01 WO PCT/EP2015/062138 patent/WO2015189063A1/en not_active Ceased
- 2015-06-01 CA CA2950804A patent/CA2950804C/en active Active
- 2015-06-01 EP EP22187393.8A patent/EP4137146A1/en active Pending
- 2015-06-01 CN CN201580030754.4A patent/CN106659743B/zh active Active
- 2015-06-01 JP JP2016572424A patent/JP6800757B2/ja active Active
-
2020
- 2020-03-24 US US16/828,121 patent/US11406669B2/en active Active
- 2020-09-28 AU AU2020244403A patent/AU2020244403B2/en active Active
- 2020-11-25 JP JP2020195123A patent/JP7009594B2/ja active Active
-
2022
- 2022-01-12 JP JP2022003013A patent/JP7279212B2/ja active Active
- 2022-07-22 US US17/870,936 patent/US12257270B2/en active Active
-
2023
- 2023-05-09 JP JP2023077363A patent/JP7680493B2/ja active Active
-
2025
- 2025-01-17 US US19/030,861 patent/US20250319134A1/en active Pending
- 2025-05-08 JP JP2025078086A patent/JP2025109787A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017526619A5 (cg-RX-API-DMAC7.html) | ||
| Donate-Correa et al. | Inflammatory cytokines in diabetic kidney disease: pathophysiologic and therapeutic implications | |
| Xiao et al. | S100 proteins in atherosclerosis | |
| Tan et al. | Curcumin relieved cisplatin-induced kidney inflammation through inhibiting Mincle-maintained M1 macrophage phenotype | |
| Chen et al. | Mitochondrial transfer as a therapeutic strategy against ischemic stroke | |
| Guo et al. | Asiatic acid ameliorates dextran sulfate sodium-induced murine experimental colitis via suppressing mitochondria-mediated NLRP3 inflammasome activation | |
| Phieler et al. | The role of the complement system in metabolic organs and metabolic diseases | |
| US20220233659A1 (en) | Oral delivery of angiotensin converting enzyme 2 (ace2) or angiotensin-(1-7)-bioencapsulated in plant cells attenuates pulmonary hypertension, cardiac dysfunction and development of autoimmune and experimentally induced ocular disorders | |
| Joviliano et al. | MicroRNAs and current concepts on the pathogenesis of abdominal aortic aneurysm | |
| JP2018505158A5 (cg-RX-API-DMAC7.html) | ||
| KR20190084056A (ko) | 인간 지방간염(nafld/nash)의 치료 및 역행을 위한 서방성 피르페니돈 함유 조성물의 약학적 용도 | |
| Schnaper | Pathophysiology of progressive renal disease in children | |
| Hara et al. | Emerging roles of protease-activated receptors in cardiometabolic disorders | |
| Wang et al. | Losartan inhibits LPS+ ATP-induced IL-1beta secretion from mouse primary macrophages by suppressing NALP3 inflammasome | |
| WO2016122806A8 (en) | Compositions and methods of using a soluble tnf-alpha receptor modified for increased half-life | |
| JP2017508455A5 (cg-RX-API-DMAC7.html) | ||
| JP2011509257A5 (cg-RX-API-DMAC7.html) | ||
| CN109453367A (zh) | 成纤维细胞生长因子21在急性肝损伤回肠粘膜损伤中的应用 | |
| JP2016504311A5 (cg-RX-API-DMAC7.html) | ||
| JP2019089759A (ja) | カジメ抽出物およびこれを活性成分として含む血管疾患を予防または処置するための医薬組成物 | |
| JP2011246454A (ja) | 安全な免疫抑制剤または免疫異常抑制剤組成物 | |
| CN109908165B (zh) | 一种含有雷公藤红素的组合物及其应用 | |
| CN109999044B (zh) | 一种含有醉茄素a的组合物及其应用 | |
| CN102579510A (zh) | 冬虫夏草的一种新用途 | |
| Yoneska et al. | The Effectiveness of Garlic Extract (Allium sativum) against Decreased Serum Levels Tumor Necrosis Factor-α (TNF-α) in Chronic Hemodialysis Patients at Dr. Mohammad Hoesin General Hospital |